Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $36 price ta...
JP Morgan analyst Benjamin Rossi assumes Surgery Partners (NASDAQ:SGRY) with a Neutral rating and announces Price Target of ...
-SEC Filing
Surgery Partners (NASDAQ:SGRY) affirms FY2025 sales outlook from $3.300 billion-$3.450 billion to $3.300 billion-$3.450 billion...
Surgery Partners (NASDAQ:SGRY) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.1...
Surgery Partners rejects Bain Capital's acquisition bid, citing greater long-term value as a public company with strong gro...
Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facil...
2025 OutlookThe Company reaffirmed its outlook for 2025 revenues and Adjusted EBITDA to be in the range of $3.30 billion to $3....
